Quick Answer
ARS Pharmaceuticals, Inc. reported Stockholders Equity of $114.26 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $114.26M | -55.5% |
| 2024 | $256.80M | +11.3% |
| 2023 | $230.76M | -15.4% |
| 2022 | $272.89M | +972.7% |
| 2021 | -$31.27M | -122.5% |
| 2020 | -$14.05M | +76.1% |
| 2019 | -$58.78M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $147.66M | -26.5% | -23.2% |
| June 30, 2025 | $192.32M | -10.6% | -16.0% |
| March 31, 2025 | $228.97M | +2.3% | -10.8% |
| December 31, 2024 | $256.80M | +11.3% | +27.8% |
| September 30, 2024 | $200.98M | -15.3% | -6.6% |
| June 30, 2024 | $215.24M | -13.4% | -3.9% |
| March 31, 2024 | $223.87M | -14.3% | -3.0% |
| December 31, 2023 | $230.76M | -15.4% | -2.7% |
- ARS Pharmaceuticals, Inc. showed a decrease of -55.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, ARS Pharmaceuticals, Inc.’s stockholders equity has grown by 294.4% (from -$58.78 million to $114.26 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: